A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radiolabeled with Copper‐64 with High Tumor Uptake and Retention

Molecules containing lysine‐ureido‐glutamate functional groups bind to the active site of prostate specific membrane antigen, which is overexpressed in prostate cancer. To prepare copper radiopharmaceuticals for the diagnosis and therapy of prostate cancer, macrobicyclic sarcophagine ligands tethere...

Full description

Saved in:
Bibliographic Details
Published in:Angewandte Chemie International Edition 2019-10, Vol.58 (42), p.14991-14994
Main Authors: Zia, Nicholas A., Cullinane, Carleen, Van Zuylekom, Jessica K., Waldeck, Kelly, McInnes, Lachlan E., Buncic, Gojko, Haskali, Mohammad B., Roselt, Peter D., Hicks, Rodney J., Donnelly, Paul S.
Format: Article
Language:English
Subjects:
Antigens
bioinorganic chemistry
Coordination compounds
Copper
Copper compounds
Diagnostic systems
Dosimeters
Dosimetry
Functional groups
imaging agents
Ligands
Lysine
macrocyclic ligands
Prostate cancer
radiopharmaceuticals
Retention
Therapy
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Molecules containing lysine‐ureido‐glutamate functional groups bind to the active site of prostate specific membrane antigen, which is overexpressed in prostate cancer. To prepare copper radiopharmaceuticals for the diagnosis and therapy of prostate cancer, macrobicyclic sarcophagine ligands tethered to either one or two lysine‐ureido‐glutamate functional groups through an appropriate linker have been prepared. Sarcophagine ligands can be readily radiolabeled with positron‐emitting copper‐64 at room temperature. The bivalent agent, in which two targeting groups are tethered to a single copper complex, dramatically outperforms the monomeric agent with respect to tumor uptake and retention. The high tumor uptake, low background, and prolonged tumor retention, even at 24 hours post injection, suggest the bivalent agent is a promising diagnostic for prostate cancer and could be used for prospective dosimetry for therapy with a copper‐67 variant. A potential imaging and therapeutic agent for prostate cancer, with high tumor uptake and retention, has been prepared by tethering two lysine‐ureido‐glutamate peptides, which bind to prostate specific membrane antigen, to a single sarcophagine–copper complex.
ISSN:1433-7851
1521-3773
DOI:10.1002/anie.201908964